Increased serum glutamate in depressed patients - PubMed (original) (raw)

• PMID: 6133511
• DOI: 10.1007/BF00345492

Increased serum glutamate in depressed patients

J S Kim et al. Arch Psychiatr Nervenkr (1970). 1982.

Abstract

Glutamate concentration was determined in serum from endogenous and neurotic depressive patients, in persons with schizophrenia or schizoaffective disorder, and in normal subjects. The mean serum glutamate level in the endogenous and neurotic depressive patients was found to be significantly higher than in any of the other groups. No other statistically significant differences were found. Statistical analysis revealed that the elevated serum glutamate concentration in the endogenous and neurotic depressive patients was probably caused by medication. These results are discussed in view of the effect of antidepressants upon the serum glutamate in the affective disorders.

PubMed Disclaimer

Similar articles

• Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder.
  Palomino A, González-Pinto A, Aldama A, González-Gómez C, Mosquera F, González-García G, Matute C. Palomino A, et al. Schizophr Res. 2007 Sep;95(1-3):174-8. doi: 10.1016/j.schres.2007.06.012. Epub 2007 Jul 13. Schizophr Res. 2007. PMID: 17630258
• Serotonergic function in the affective disorders: the effect of antidepressants and lithium on the 5-hydroxytryptophan-induced increase in serum cortisol.
  Meltzer HY. Meltzer HY. Ann N Y Acad Sci. 1984;430:115-37. doi: 10.1111/j.1749-6632.1984.tb14502.x. Ann N Y Acad Sci. 1984. PMID: 6378031 Review. No abstract available.
• Prolactin response to thyrotropin-releasing hormone in schizoaffective depressed compared to depressed and schizophrenic men and healthy controls.
  Wahby VS, Ibrahim GA, LeeChuy I, Saddik FW, Giller EL, Mason JW. Wahby VS, et al. Schizophr Res. 1990 Oct-Dec;3(5-6):277-81. doi: 10.1016/0920-9964(90)90010-5. Schizophr Res. 1990. PMID: 2126454
• Altered platelet 3H-imipramine binding in schizo-affective and depressive disorders.
  Suranyi-Cadotte BE, Wood PL, Schwartz G, Nair NP. Suranyi-Cadotte BE, et al. Biol Psychiatry. 1983 Aug;18(8):923-7. Biol Psychiatry. 1983. PMID: 6311293 No abstract available.
• [Schizoaffective disorder: clinical symptoms and present-day approach to treatment].
  Danileviciūte V. Danileviciūte V. Medicina (Kaunas). 2002;38(11):1057-65. Medicina (Kaunas). 2002. PMID: 12532717 Review. Lithuanian.

Cited by

• Enzymatic activity of palmitoyl-protein thioesterase-1 in serum from schizophrenia significantly associates with schizophrenia diagnosis scales.
  Wu Y, Zhang Q, Qi Y, Gao J, Li W, Lv L, Chen G, Zhang Z, Yue X, Peng S. Wu Y, et al. J Cell Mol Med. 2019 Sep;23(9):6512-6518. doi: 10.1111/jcmm.14496. Epub 2019 Jul 3. J Cell Mol Med. 2019. PMID: 31270934 Free PMC article.
• The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.
  Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, Caloro M, Telesforo CL, Caltagirone SS, Panaccione I, Simonetti A, Demontis F, Serra G, Girardi P. Sani G, et al. CNS Drugs. 2012 Aug 1;26(8):663-90. doi: 10.2165/11634390-000000000-00000. CNS Drugs. 2012. PMID: 22784018 Review.
• Evaluation of Clinical Factors Associated with Adverse Drug Events in Patients Receiving Sub-Anesthetic Ketamine Infusions.
  Stoker AD, Rosenfeld DM, Buras MR, Alvord JM, Gorlin AW. Stoker AD, et al. J Pain Res. 2019 Dec 23;12:3413-3421. doi: 10.2147/JPR.S217005. eCollection 2019. J Pain Res. 2019. PMID: 31920366 Free PMC article.
• The possible place for psychedelics in pharmacotherapy of mental disorders.
  Wojtas A. Wojtas A. Pharmacol Rep. 2023 Dec;75(6):1313-1325. doi: 10.1007/s43440-023-00550-9. Epub 2023 Nov 7. Pharmacol Rep. 2023. PMID: 37934320 Free PMC article. Review.
• The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
  Halaris A, Cook J. Halaris A, et al. Adv Exp Med Biol. 2023;1411:487-512. doi: 10.1007/978-981-19-7376-5_21. Adv Exp Med Biol. 2023. PMID: 36949323

References

1. 1. J Psychiatr Res. 1974;11:249-53 - PubMed
2. 1. J Neural Transm. 1975;37(2):95-109 - PubMed
3. 1. Nature. 1970 Mar 28;225(5239):1259-60 - PubMed
4. 1. Lancet. 1972 Dec 30;2(7792):1415-6 - PubMed
5. 1. Science. 1972 Mar 24;175(4028):1380-2 - PubMed

MeSH terms

Substances